TITLE

IMPORTANT CORRECTION OF INFORMATION ABOUT ATROVENT AND COMBIVENT INHALATION AEROSOLS

PUB. DATE
August 2005
SOURCE
Mayo Clinic Proceedings;Aug2005, Vol. 80 Issue 8, p1048
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents important correction of information about atrovent and combivent inhalation aerosols. In previous issues of the journal "Mayo Clinic Proceedings," Boehringer Ingelheim Pharmaceuticals Inc. placed an advertisement for Atrovent Inhalation Aerosol and Combivent Inhalation Aerosol, identified with the heading "Air: Essential for Life," that the U.S. Food and Drug Administration (FDA) determined violated the provisions of the drug advertising and promotion regulations. This advertisement was the subject of a warning letter from the FDA, which concluded that the advertisement was false or misleading because it made unsubstantiated effectiveness claims for, and omitted material facts about, Atrovent Inhalation Aerosol and Combivent Inhalation Aerosol.
ACCESSION #
17998154

 

Related Articles

  • Combivent Respimat Transition.  // Monthly Prescribing Reference;Jun2013, Vol. 29 Issue 6, pA31 

    The article informs that Boehringer Ingelheim Pharmaceuticals Inc. has completed the manufacturing of the Combivent Respimat Inhalation Spray.

  • Pradaxa.  // Pharmaceutical Representative;Nov2010, Vol. 40 Issue 11, p10 

    The article reports on the approval of Boehringer Ingelheim Pharmaceutical Inc.'s Pradaxa capsules by the U.S. Food and Drug Administration (FDA), the drug is used for the prevention of blood clots and stroke in patients with abnormal heart rhythm.

  • Product news.  // Medical Marketing & Media;May99, Vol. 34 Issue 5, p21 

    Presents an update on drug reviews and approvals in the United States, as of May 1999. Includes the US Food and Drug Administration's (FDA) approval of a new indication for Novartis' cholesterol-lowering medication Lescol; Boehringer Ingelheim Pharmaceuticals Inc.'s receipt of priority review...

  • FDA panel recommends approval of tipranavir. Roehr, Bob // Bay Area Reporter;5/26/2005, Vol. 35 Issue 21, p16 

    Reports on the United States Food and Drug Administration's pending approval of the protease inhibitor tipranavir (trade name Aptivus) for use in salvage therapy for HIV. Advisory committee's concern and reservations to recommend that approval; Boehringer Ingelheim Pharmaceutical Inc.'s...

  • New drugs.  // Drug Topics;Mar2012, Vol. 156 Issue 3, p74 

    The article offers brief information on several new drugs that have been approved by the U.S. Food & Drug Administration (FDA), including the drug Kalydeco from Vertex Pharmaceuticals Inc., Jentadueto from Boehringer Ingelheim Pharmaceuticals Inc., and Inlyta from Pfizer Inc.

  • FDA actions.  // Neurology Alert;Dec2010 Supplement, p2 

    This section presents an update on drug approvals and other related issues made by the U.S. Food and Drug Administration (FDA). It details the approval given by the FDA for fingolimod, a drug used for the treatment of relapsing forms of multiple sclerosis. Information is also given on the...

  • Pharma: Other News To Note.  // BioWorld Today;9/18/2013, Vol. 24 Issue 179, p5 

    The article offers information the breakthrough therapy designation granted to the volasertib drug of Boehringer Ingelheim Pharmaceuticals Inc. and the drug approval of Treanda (bendamustine HCI) injection from Teva Pharmaceutical Industries Ltd. by the U.S. Food and Drug Administration (FDA).

  • FDA OKs Boehringer Ingelheim atrial fibrillation pill. Soule, Alexander // Fairfield County Business Journal;11/1/2010, Vol. 49 Issue 44, p11 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) on Pradaxa, formulated in capsules by Boehringer Ingelheim Pharmaceuticals Inc. to prevent stroke in patients with abnormal heart rhythm in Fairfield County, Connecticut in 2010.

  • Recently Approved.  // Pharmaceutical Representative;Aug2008, Vol. 38 Issue 8, p14 

    The article offers information on medicines approved by the U.S. Food and Drug Administration (FDA) for use in treating various diseases. Accordingly, the FDA has approved Eli Lilly's Cymbalta from for the treatment of fibromyalgia. Moreover, it states that Avodart from GlaxoSmithKline has been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics